Literature DB >> 18760862

Identification of hydrolytically stable and selective P2Y(1) receptor agonists.

Shay E Eliahu1, Jean Camden, Joanna Lecka, Gary A Weisman, Jean Sévigny, Sylvie Gélinas, Bilha Fischer.   

Abstract

P2Y nucleotide receptors (P2YRs) are attractive pharmaceutical targets. Most P2YR agonists proposed as drugs consist of a nucleotide scaffold, but their use is limited due to their chemical and enzymatic instabilities. To identify drug candidates, we developed non-hydrolyzable P2YR agonists. We synthesized ATP-beta,gamma-CH(2) analogues 2-4, and evaluated their chemical and metabolic stabilities and activities at P2Y(1,2,4,6) receptors. Analogues 2-4 exhibited t(1/2) values of 14.5-65 h in gastric juice pH. They were completely resistant to alkaline phosphatase for 30 min at 37 degrees C and slowly hydrolyzed in human blood serum (t(1/2) 12.7-71.9 h). In comparison to ATP, analogues 2-4 were barely hydrolyzed by nucleoside triphosphate diphosphohydrolases, NTPDase1,2,3,8 (< 8% hydrolysis), and nucleotide pyrophosphatases, NPP1,3 (< or = 10% hydrolysis). Analogues 2 and 4B were selective agonists of the P2Y(1)R with EC(50)s of 0.08 and 17.2 microM, respectively. These features make analogues 2 and 4B potential therapeutic agents for health disorders involving the P2Y(1)R.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760862      PMCID: PMC4354951          DOI: 10.1016/j.ejmech.2008.07.015

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  63 in total

1.  Enzymatic and transcriptional regulation of human ecto-ATPase/E-NTPDase 2.

Authors:  Aileen F Knowles; Wei-Chieh Chiang
Journal:  Arch Biochem Biophys       Date:  2003-10-15       Impact factor: 4.013

2.  Synthesis of nucleoside alpha-thiotriphosphates via an oxathiaphospholane approach.

Authors:  Konrad Misiura; Daria Szymanowicz; Wojciech J Stec
Journal:  Org Lett       Date:  2005-05-26       Impact factor: 6.005

3.  The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.

Authors:  Arvydas Maminishkis; Stephen Jalickee; Sasha A Blaug; Jodi Rymer; Benjamin R Yerxa; Ward M Peterson; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-11       Impact factor: 4.799

4.  Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions.

Authors:  G G Yegutkin; T Henttinen; S Jalkanen
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

5.  Identification and characterization of CD39/vascular ATP diphosphohydrolase.

Authors:  E Kaczmarek; K Koziak; J Sévigny; J B Siegel; J Anrather; A R Beaudoin; F H Bach; S C Robson
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

6.  Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5'-O-(1-boranotriphosphate) derivatives.

Authors:  M E Tulapurkar; W Laubinger; V Nahum; B Fischer; G Reiser
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

7.  Structure Activity Relationships for Derivatives of Adenosine-5'-Triphosphate as Agonists at P(2) Purinoceptors: Heterogeneity Within P(2X) and P(2Y) Subtypes.

Authors:  Geoffrey Burnstock; Bilha Fischer; Charles H V Hoyle; Michel Maillard; Airat U Ziganshin; Antonia L Brizzolara; Amy von Isakovics; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  2004-10-05       Impact factor: 4.360

8.  The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells.

Authors:  Gennady G Yegutkin; Tiina Henttinen; Sergei S Samburski; Jozef Spychala; Sirpa Jalkanen
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

9.  Hydrolysis of P2-purinoceptor agonists by a purified ectonucleotidase from the bovine aorta, the ATP-diphosphohydrolase.

Authors:  M Picher; J Sévigny; P D'Orléans-Juste; A R Beaudoin
Journal:  Biochem Pharmacol       Date:  1996-06-14       Impact factor: 5.858

10.  Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases.

Authors:  S A Lévesque; E G Lavoie; J Lecka; F Bigonnesse; J Sévigny
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

View more
  10 in total

1.  Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.

Authors:  Hiroshi Maruoka; Matthew O Barrett; Hyojin Ko; Dilip K Tosh; Artem Melman; Lauren E Burianek; Ramachandran Balasubramanian; Barkin Berk; Stefano Costanzi; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

2.  A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold.

Authors:  Shay Eliahu; Haim M Barr; Jean Camden; Gary A Weisman; Bilha Fischer
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

3.  2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.

Authors:  Shay Eliahu; Alba Martín-Gil; María Jesús Perez de Lara; Jesús Pintor; Jean Camden; Gary A Weisman; Joanna Lecka; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

Review 4.  P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.

Authors:  Gary A Weisman; Lucas T Woods; Laurie Erb; Cheikh I Seye
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-09       Impact factor: 4.388

5.  Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.

Authors:  Shir Yelovitch; Haim M Barr; Jean Camden; Gary A Weisman; Ela Shai; David Varon; Bilha Fischer
Journal:  J Med Chem       Date:  2012-08-20       Impact factor: 7.446

6.  Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.

Authors:  Yael Nadel; Joanna Lecka; Yocheved Gilad; Gal Ben-David; Daniel Förster; Georg Reiser; Sarah Kenigsberg; Jean Camden; Gary A Weisman; Hanoch Senderowitz; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2014-05-30       Impact factor: 7.446

7.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

8.  Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1/A3 receptors in physiology and pathology.

Authors:  Theodore E Liston; Sonja Hinz; Christa E Müller; Deborah M Holstein; Jay Wendling; Roger J Melton; Mary Campbell; William S Korinek; R Rama Suresh; Dane A Sethre-Hofstad; Zhan-Guo Gao; Dilip K Tosh; Kenneth A Jacobson; James D Lechleiter
Journal:  Purinergic Signal       Date:  2020-10-31       Impact factor: 3.765

9.  Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.

Authors:  Arijit Das; Hyojin Ko; Lauren E Burianek; Matthew O Barrett; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

Review 10.  Overview of Biologically Active Nucleoside Phosphonates.

Authors:  Elisabetta Groaz; Steven De Jonghe
Journal:  Front Chem       Date:  2021-01-08       Impact factor: 5.221

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.